🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against superbug strains of the pathogen, according to health experts.

An International Challenge

The sexually transmitted infection are increasing globally, with figures suggesting more than 82 million new cases each year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, was also approved in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This authorization marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Results and Global Access

As per results detailed in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which involves an injection and a pill. The trial included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in numerous developing nations.

Medical professionals directly involved have voiced hope. Access to a easy-to-administer therapy such as this is seen as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.